Menarini Group to Acquire Kura Oncology for $1.1 Billion

TL;DR

Menarini buying Kura Oncology for $1.1B cash ($9/share), deal expected Q3.

AI Summary

Kura Oncology, Inc. announced on May 24, 2024, that it has entered into a definitive agreement to be acquired by Menarini Group. The transaction is valued at approximately $1.1 billion, with Menarini Group offering $9.00 per share in cash for all outstanding shares of Kura Oncology. The acquisition is expected to close in the third quarter of 2024, subject to customary closing conditions.

Why It Matters

This acquisition by Menarini Group represents a significant cash premium for Kura Oncology shareholders and could lead to the advancement of Kura's pipeline drugs under a larger pharmaceutical entity.

Risk Assessment

Risk Level: medium — The deal is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the acquisition.

Key Numbers

• $1.1B — Acquisition Value (Total cash consideration for Kura Oncology)
• $9.00 — Per Share Price (Cash offered for each Kura Oncology share)

Key Players & Entities

• Kura Oncology, Inc. (company) — Company being acquired
• Menarini Group (company) — Acquiring company
• $1.1 billion (dollar_amount) — Total acquisition value
• $9.00 (dollar_amount) — Per share acquisition price
• May 24, 2024 (date) — Date of announcement
• third quarter of 2024 (date) — Expected closing period

FAQ

Key Financial Figures

• $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se

Filing Documents

• d842527d8k.htm (8-K) — 24KB
• 0001193125-24-147030.txt ( ) — 143KB
• kura-20240524.xsd (EX-101.SCH) — 3KB
• kura-20240524_lab.xml (EX-101.LAB) — 18KB
• kura-20240524_pre.xml (EX-101.PRE) — 11KB
• d842527d8k_htm.xml (XML) — 4KB

Forward-Looking Statements

Forward-Looking Statements Any forward-looking statements in this Current Report on Form 8-K are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: uncertainties associated with performing clinical trials and risks associated with reliance on third parties to successfully conduct clinical trials, as well as those risks and uncertainties set forth more fully under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 filed with the Securities and Exchange Commission ("SEC") on May 2, 2024, as well as discussions of potential risks, uncertainties and other important factors in the Company's other filings and reports with the SEC. All forward-looking statements contained in this Current Report on Form 8-K speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. KURA ONCOLOGY, INC. Date: May 24, 2024 By: /s/ Teresa Bair Teresa Bair Chief Legal Officer

View Full Filing

View this 8-K filing on SEC EDGAR